UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
------------------------
Date of Report (Date of earliest event reported): March 30, 2004
IMPAX LABORATORIES, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-27354 65-0403311
- ------------------------------- ------------ ----------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification Number)
30381 Huntwood Avenue
Hayward, CA 94544
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (510) 476-2000
--------------
Item 9. Regulation FD Disclosure
On March 30, 2004, Impax Laboratories, Inc. (the "Company") issued a
press release announcing the pricing of its private offering of $82 million
aggregate principal amount of 1.250% convertible senior subordinated debentures
due 2024. A copy of the press release is attached as Exhibit 99.1 and is
incorporated herein by reference.
This exhibit is not filed, but is furnished to comply with Regulation
FD. The information disclosed in this Item 9 Current Report on Form 8-K is not
considered to be "filed" for purposes of Section 18 of the Securities and
Exchange Act of 1934 and is not subject to the liabilities of that section.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: March 30, 2004
By: /s/ Barry R. Edwards
-------------------------
Barry R. Edwards
Chief Executive Officer